Core Viewpoint - The Gross Law Firm is notifying shareholders of Semtech Corporation regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's CopperEdge products [1][2]. Group 1: Allegations - The complaint alleges that during the class period from August 27, 2024, to February 7, 2025, Semtech's CopperEdge products did not meet the needs of its server rack customers or end users [1]. - It is claimed that the CopperEdge products required specific rack architecture changes, which were not disclosed [1]. - As a result of these issues, the sales of CopperEdge products are expected to be lower than anticipated, impacting the company's performance in fiscal 2026 [1]. Group 2: Class Action Details - Shareholders who purchased shares of Semtech during the specified class period are encouraged to register for the class action, with a deadline of April 22, 2025, to seek lead plaintiff status [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - GSK plc is facing allegations related to misleading statements about the safety of Zantac, which may have led to investor losses during the specified class period from February 5, 2020, to August 14, 2022 [1] Group 1: Allegations and Legal Context - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac from the market, claiming it was based on available information and regulatory correspondence, while being aware of the source of NDMA for nearly 40 years [1] - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which the complaint argues was materially false or misleading [1] - The company claimed it could not quantify or reliably estimate its liability, which is also contested in the allegations [1] Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the class period are encouraged to register for the class action, with a deadline of April 7, 2025, to seek lead plaintiff status [2] - Registered shareholders will receive updates through portfolio monitoring software regarding the case's progress [2] Group 3: Law Firm's Mission and Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [3] - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated GSK's stock price [3]

Core Viewpoint - The Trade Desk, Inc. is facing allegations of issuing materially false and misleading statements regarding its AI forecasting tool, Kokai, which has led to execution challenges and negatively impacted revenue growth [1]. Group 1: Allegations and Issues - The complaint alleges that during the class period from May 9, 2024, to February 12, 2025, The Trade Desk experienced significant execution challenges in rolling out its AI tool, Kokai, transitioning clients from the older platform, Solimar [1]. - These execution challenges delayed the Kokai rollout, which in turn negatively impacted the company's business operations and revenue growth [1]. - The positive statements made by the defendants about the company's business and prospects were claimed to be materially false and misleading due to the aforementioned issues [1]. Group 2: Shareholder Information - Shareholders who purchased shares of TTD during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, with a deadline set for April 21, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Integral Ad Science Holding Corp. (NASDAQ: IAS) about a class action lawsuit due to allegations of misleading statements and competitive pricing pressures affecting the company's performance during the specified class period [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 2, 2023, to February 27, 2024 [2]. - Allegations include that IAS faced increased competitive pricing pressures, leading to price cuts due to weakening demand and slowing revenue growth [2]. - It is claimed that IAS's pricing function was no longer favorable, impacting its ability to sustain pricing and drive increases [2]. - Pricing became a critical differentiator for IAS in closing major renewals and new deals, and the risks of increased pricing pressure had materialized [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 31, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for the shareholders [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered from deceit, fraud, and illegal business practices [4]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [4].

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Newmont Corporation (NYSE: NEM).Shareholders who purchased shares of NEM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/newmont-corporation-loss-submission-form/?id=134047&from=4 CLASS PERIOD: February 22, 202 ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=134054&from=4 CLASS PERIOD: February 3, 2022 to Febru ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Monolithic Power Systems Inc. (NASDAQ: MPWR).Shareholders who purchased shares of MPWR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/monolithic-loss-submission-form/?id=134049&from=4 CLASS PERIOD: February 8, ...

Core Viewpoint - FMC Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its business operations and channel management initiatives during the class period from November 16, 2023, to February 4, 2025 [1] Group 1: Allegations - The complaint alleges that FMC's channel management initiatives were not progressing as represented [1] - The company decided not to compete on prices due to pricing pressure, leading to missed sales opportunities [1] - There was inflated inventory in channels across Latin America, Asia, Canada, and Eastern Europe [1] - Positive statements made by the defendants about FMC's business and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased FMC shares during the specified class period are encouraged to register for the class action [2] - The deadline for shareholders to seek lead plaintiff status is April 14, 2025 [2] - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Semtech Corporation (NASDAQ: SMTC).Shareholders who purchased shares of SMTC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/semtech-corporation-loss-submission-form/?id=134061&from=4CLASS PERIOD: August 27, 20 ...

Core Viewpoint - Novo Nordisk A/S faced a significant drop in stock price following the announcement of disappointing results from their "REDEFINE 1" trial, which investigated the efficacy of CagriSema for weight loss [1] Group 1: Trial Results - The "REDEFINE 1" trial showed that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, falling short of the company's target of at least 25% [1] - Only 57.3% of patients in the trial were on the highest dosage of CagriSema, as participants were allowed to modify their own dosage during the trial [1] Group 2: Stock Price Impact - Following the press release regarding the trial results, Novo's stock price decreased by $18.44 per share, closing at $85.00 per share [1] Group 3: Class Action Information - Shareholders who purchased shares of NVO during the class period from November 2, 2022, to December 19, 2024, are encouraged to register for a class action lawsuit [2] - The deadline for shareholders to seek lead plaintiff status is March 25, 2025, and there is no cost or obligation to participate in the case [2]